Obviousness

Obviousness Analysis (35 U.S.C. § 103) for US12569490

To establish obviousness under 35 U.S.C. § 103, it must be shown that the claimed invention as a whole would have been obvious to a person having ordinary skill in the art at the time of the invention. This requires demonstrating: (1) that the prior art discloses all the elements recited in the claim, (2) that there would have been a motivation to combine these prior art references to produce the claimed invention, and (3) a reasonable expectation that the combination would be successful.

The independent claims of US12569490 are directed to methods of treating or preventing testicular adrenal rest tumors (TART) or ovarian adrenal rest tumors (OART) by administering a corticotropin-releasing factor type-1 (CRF1) antagonist or a pharmaceutically acceptable salt thereof (Claim 1), or a pharmaceutical composition comprising a compound of structural Formula (I) and a pharmaceutically acceptable excipient (Claim 10).

Prior Art Landscape

Congenital Adrenal Hyperplasia (CAH) due to 21-hydroxylase deficiency is a genetic disorder characterized by impaired cortisol synthesis, leading to overproduction of ACTH and adrenal androgens. TART and OART are known complications of CAH, developing from adrenal tissue stimulated by high ACTH levels. Current CAH treatments involve glucocorticoid replacement therapy to suppress ACTH and androgen production, often requiring supraphysiological doses with associated adverse effects. The need for novel therapies to address these issues and improve outcomes for CAH patients is well-recognized.

CRF1 antagonists have been investigated for their potential to inhibit ACTH release in CAH patients, thereby allowing for lower, more physiological glucocorticoid doses and reducing side effects. Prior art already discloses methods for treating CAH by administering a CRF1 antagonist, including bedtime administration.

Obviousness of Claim 1

Claim 1: "A method of treating or preventing testicular adrenal rest tumors (TART) or ovarian adrenal rest tumors (OART), comprising administering to a subject in need thereof a corticotropin-releasing factor type-1 (CRF1) antagonist or a pharmaceutically acceptable salt thereof."

Combination of References: US20170020877A1 and general knowledge in the art regarding CAH and its complications.

Analysis:

1. Disclosure of Elements:
   • Treating or preventing TART or OART: The patent US12569490 explicitly states that TART and OART are ACTH-responsive lesions and a complication of CAH. In the treatment of CAH, reducing ACTH levels is a primary goal.
   • Administering a CRF1 antagonist or a pharmaceutically acceptable salt thereof: US20170020877A1 explicitly discloses methods for treating CAH by administering an effective amount of a CRF1 antagonist or a pharmaceutically acceptable salt thereof. It also highlights that "CRF1 antagonists have the potential to directly inhibit ACTH release in patients with CAH".
2. Motivation to Combine: A person having ordinary skill in the art (POSA) would have been motivated to combine the knowledge of TART/OART as an ACTH-responsive complication of CAH with the known mechanism of action of CRF1 antagonists in suppressing ACTH.
   • The "nature of the problem to be solved" provides a clear motivation. TART and OART are caused by hyperplasia of adrenal tissue in response to high ACTH. Conventional glucocorticoid therapy for CAH, while aiming to suppress ACTH, often requires supraphysiological doses with undesirable side effects.
   • US20170020877A1 explicitly states that CRF1 antagonists "have the potential to directly inhibit ACTH release in patients with CAH, thereby allowing normalization of androgen production while using lower, more physiologic doses of hydrocortisone, and reducing treatment-associated side effects." This statement directly links CRF1 antagonism to addressing the underlying hormonal imbalances in CAH, which are also responsible for TART/OART development. Therefore, a POSA would have a clear motivation to apply a CRF1 antagonist, known to reduce ACTH in CAH patients, to treat or prevent TART/OART, which are directly driven by elevated ACTH in the context of CAH.
3. Reasonable Expectation of Success: Given that TART/OART are explicitly identified as ACTH-responsive lesions in patients with CAH, and CRF1 antagonists are known to inhibit ACTH release in CAH patients, a POSA would have a reasonable expectation of success in using CRF1 antagonists to treat or prevent these tumors. The mechanism of action is directly targeted at the known physiological cause of the tumors in the context of CAH.

Therefore, Claim 1 appears to be obvious in light of US20170020877A1 and the general understanding of CAH and its complications in the art.

Obviousness of Claim 10

Claim 10: "A method of treating or preventing testicular adrenal rest tumors (TART) or ovarian adrenal rest tumors (OART), comprising administering to a subject in need thereof a pharmaceutical composition, comprising a compound of structural Formula (I): [chemical structure] or a pharmaceutically acceptable salt thereof, wherein: R1 and R2 are independently ethyl or n-propyl; R3 is hydrogen, Cl, Br, methyl, trifluoromethyl, or methoxy; and R4 is hydrogen, Br, RaRbN—, methoxymethyl, n-butyl, acetamido, pyridin-4-yl, morpholin-4-yl, [chemical structure] Ra and Rb are independently hydrogen, C1-C3 alkyl, H2NCH2CH2—, (CH3)3COC(O)NHCH2CH2—, or CH3CH2CH2NHCH2CH2—."

Combination of References: US20170020877A1, additional prior art disclosing compounds of Formula (I) as CRF1 antagonists, and general knowledge in the art.

Analysis:

1. Disclosure of Elements:
   • Treating or preventing TART or OART: As discussed for Claim 1, the link between CAH, elevated ACTH, and TART/OART is established in the prior art.
   • Administering a pharmaceutical composition comprising a compound of structural Formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient: The patent itself refers to "Compound 1" as a "potent, selective, nonsteroidal, oral corticotropin-releasing factor type-1 (CRF1) receptor antagonist" and uses it in various figures and examples related to ACTH, 17-OHP, and androstenedione levels, and even TART images. The compounds described by Formula (I) in US12569490 are clearly identified as CRF1 antagonists. If specific compounds falling under Formula (I) were known in the prior art as CRF1 antagonists, and their use in treating CAH was also known (as suggested by US20170020877A1), then the administration of such a compound in a pharmaceutical composition would be a combination of known elements.
2. Motivation to Combine: The motivation to use a specific CRF1 antagonist, such as those covered by Formula (I), for treating TART/OART in CAH patients stems from the same reasoning as for Claim 1. If a compound of Formula (I) was known to be a CRF1 antagonist and was considered for CAH treatment, then its application to a known complication of CAH (TART/OART) would be a logical extension.
3. Reasonable Expectation of Success: If compounds of Formula (I) were already established as effective CRF1 antagonists in the context of CAH (e.g., in reducing ACTH and downstream hormones), a POSA would have a reasonable expectation that these compounds would also be effective in treating or preventing ACTH-responsive TART/OART.

To definitively establish obviousness for Claim 10, one would need to demonstrate that specific compounds encompassed by Formula (I) were known CRF1 antagonists in the prior art, and ideally, their utility in modulating ACTH or treating CAH was also known prior to the priority date of US12569490 (2018-04-27). While US20170020877A1 broadly discusses CRF1 antagonists for CAH, it does not explicitly disclose the specific structural Formula (I) or the compounds exemplified within US12569490. However, if prior art existed that disclosed compounds matching Formula (I) as CRF1 antagonists (for any indication, or even specifically for CAH), then applying them to the ACTH-driven TART/OART in CAH patients would be obvious for the reasons outlined above. A "patent review" from Scilit mentions "non-peptide CRF1 antagonists in the patent literature since 2006" but doesn't disclose specific structures matching Formula (I). "Progress in corticotropin-releasing factor-1 antagonist development" also discusses CRF1 antagonists generally.

Conclusion on Obviousness:

Based on the available prior art, Claim 1 appears to be obvious because the use of CRF1 antagonists to reduce elevated ACTH in CAH is a known approach, and TART/OART are well-established ACTH-driven complications of CAH. A POSA would be motivated to use a known ACTH-suppressing agent for an ACTH-dependent condition.

For Claim 10, the obviousness hinges on whether the specific compounds of Formula (I) were already known CRF1 antagonists in the prior art before the priority date. If so, the application of such known CRF1 antagonists for treating TART/OART in CAH patients would be obvious for the reasons described for Claim 1. Without specific prior art disclosing compounds of structural Formula (I) as CRF1 antagonists, a stronger case for non-obviousness could be made for Claim 10 if the specific structural features of Formula (I) are novel and non-obvious as CRF1 antagonists.